EDNRB and neoplasm: The addition of an ETBR agonist to the treatment was an attempt to improve drug penetration and distribution in the tumor, as failure to achieve adequate cytotoxic concentrations in the tumor has been identified as a potential mechanism mediating treatment failure in bile duct cancer.